Novo Nordisk Slashes Ozempic and Wegovy Prices Up to 48% in India
Novo Nordisk cut Ozempic prices 36% and Wegovy 48% in India as generic semaglutide from Dr Reddy's, Sun Pharma, and Zydus entered the market with prices as low as Rs 1,290/month.
#Wegovy
44 stories
Wegovy is Novo Nordisk's branded semaglutide for chronic weight management. The injectable form launched in 2021. Oral Wegovy — a reformulated, higher-dose oral semaglutide — launched in late 2025 and early 2026, with the 1.5mg starter dose at $149/month and the 4mg dose moving from $149 to $199 effective April 15, 2026.
The most cited Wegovy data: SELECT (20% MACE reduction in non-diabetic adults with obesity), the STEP series for weight loss, and recent comparative work suggesting oral Wegovy may edge ahead of Foundayo (orforglipron) on weight loss despite Foundayo's HbA1c lead. Wegovy is on the FDA's April 30 proposal to exclude semaglutide from the 503B bulks list — the compounded-Wegovy market has been a core revenue threat for Novo.
Stories here cover pricing, head-to-head readouts, payer coverage, and the compounding economics.
UK Expands Wegovy Prescribing for Cardiovascular Prevention
Under new UK guidance, GPs can prescribe semaglutide (Wegovy) to overweight patients who have had heart attacks, strokes, or serious circulation problems, expanding its use beyond weight management.
FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss
The FDA approved once-daily oral semaglutide (Wegovy) 25 mg as the first GLP-1 pill for weight loss, offering a convenient alternative to injections with comparable weight loss to the original injection.
FDA Approves Oral Wegovy Following Positive OASIS 4 Trial Results
FDA approved oral Wegovy (semaglutide) based on OASIS 4 trial showing significant improvements in glycemic control and cardiovascular risk factors. Novo Nordisk plans full US launch from North Carolina manufacturing.
5 Things to Know About the Oral GLP-1 Era
AJMC covers the oral GLP-1 era: participants on 25mg oral semaglutide saw ~16.6% weight loss when adherent, comparable to injectable outcomes. Discusses broader market implications.
Hims & Hers Now Offers Novo Nordisk's FDA-Approved GLP-1 Medications
Hims & Hers announced Novo Nordisk's approved GLP-1 medications including Wegovy injections/pills and Ozempic are now available through its platform at lower-than-retail rates.
Novo Nordisk to Slash US List Prices ~50% for Wegovy, Ozempic, and Rybelsus in 2027
Novo will reduce prices to $675/month starting January 1, 2027 — approximately 50% cut for Wegovy and 35% for Ozempic, aimed at patients on high-deductible plans.
Medicare to Cover GLP-1 Weight Loss Drugs at $50/Month Starting July 2026
CMS confirmed that Medicare Part D beneficiaries will gain access to Wegovy and Zepbound for weight loss through the Medicare GLP-1 Bridge program starting July 2026 at a $50 monthly copayment, bridging to the full BALANCE Model launching in Medicare Part D in January 2027.